BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On July 1, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced the finalization of its acquisition of Inozyme Pharma, Inc.

The deal is valued at $270 million, and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has paid $4.00 per share in cash for all Inozyme shares. This acquisition brings a new medicine, INZ-701, into the company’s portfolio. INZ-701 is an enzyme replacement therapy in late-stage development. The drug targets ENPP1 Deficiency, which is a rare and severe genetic disorder that affects blood vessels, soft tissues, and bones.

The process began on May 16, 2025, when both companies announced a merger agreement. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) then started a tender offer on June 2, 2025, and shareholders were offered $4.00 per share. The offer ended on June 30, 2025.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is an international biotechnology company focused on developing and commercializing innovative therapies for rare genetic disorders.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.